Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Long term Global Blood Therapeutics, Inc. (NASDAQ:GBT) shareholders know that all too well, since the share price is down considerably over three years. Sadly for them, the share price is down 58% ...

What happenedShares of hematology biotech Global Blood Therapeutics (NASDAQ: GBT) are up 16.5% as of 10:30 a.m. EDT after the company posted upbeat second-quarter 2021 earnings. Sales of its ...

Global Blood Therapeutics Inc. stock surged 5.5% in premarket trade Wednesday after the European Medicines Agency said its sickle cell disease drug is eligible for a priority drug program.

Global Blood Therapeutics said it is selling 5.1 million shares of common stock to the public for $24.50 per share. That should net the company $125 million after deducting fees.

Revisiting Global Blood Therapeutics Jul. 30, 2019 9:11 AM ET Pfizer Inc. (PFE) Stock PFE 30 Comments 3 Likes Bret Jensen Investing Group Leader ...

Syros could also co-promote the first product resulting from the collaboration in the U.S. Global Blood Therapeutics shares are down 5.5% in Wednesday premarket trading, but up 90% for the past year.

What: Global Blood Therapeutics (GBT) is down 19% at 12:30 p.m. EST after releasing data for its sickle cell drug GBT440 at the American Society of Hematology (ASH) meeting over the weekend.

Global Blood Therapeutics had been studying its main, and only, drug GBT440 in two conditions, idiopathic pulmonary fibrosis and sickle cell disease, which affect the body in different ways but ...